Classes terapêuticas que induzem a esse evento adverso
Agente antiangiogênico, Inibidor de BRAF, Inibidor de CTLA4, Quimioterapia (fluoruracila, capecitabina, dacarbazina, Tegafur, vimblastina, etc.), Inibidor de quinase dependente de ciclina 4/6, Inibidor de EGFR, Terapia hormonal, Inibidor de KIT, Inibidor de MEK, Inibidor de PD-1, Inibidor de RAF, Radioterapia, Inibidor de SMO, Inibidor de mTOR
CLASSIFICAÇÃO SIMPLIFICADA
Lesões únicas ou múltiplas com sintomas leves ou assintomáticas.
REFERÊNCIAS
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: A guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CLASSIFICAÇÃO SIMPLIFICADA
Sintomas moderados ou graves. Formação de bolha generalizada.
REFERÊNCIAS
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: A guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CLASSIFICAÇÃO SIMPLIFICADA
Risco de morte
REFERÊNCIAS
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: A guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Consulte mais efeitos colaterais